Taxol®: The first microtubule stabilizing agent

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Taxol®, an antitumor drug with significant activity, is the first microtubule stabilizing agent described in the literature. This short review of the mechanism of action of Taxol® emphasizes the research done in the Horwitz’ laboratory. It discusses the contribution of photoaffinity labeled analogues of Taxol® toward our understanding of the binding site of the drug on the microtubule. The importance of hydrogen/deuterium exchange experiments to further our insights into the stabilization of microtubules by Taxol® is addressed. The development of drug resistance, a major problem that arises in the clinic, is discussed. Studies describing differential drug binding to distinct β-tubulin isotypes are presented. Looking forward, it is suggested that the β-tubulin isotype content of a tumor may influence its responses to Taxol®.

Original languageEnglish (US)
Article number1733
JournalInternational Journal of Molecular Sciences
Volume18
Issue number8
DOIs
StatePublished - Aug 10 2017

Fingerprint

Excipients
Binding sites
Deuterium
Paclitaxel
Microtubules
Tumors
drugs
Stabilization
Hydrogen
Tubulin
Experiments
Pharmaceutical Preparations
deuterium
tumors
Drug Resistance
stabilization
Antineoplastic Agents
analogs
Binding Sites
hydrogen

Keywords

  • Drug binding site
  • Drug resistance
  • Photoaffinity labeling
  • Taxol®
  • Tubulin isotypes

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Taxol® : The first microtubule stabilizing agent. / Yang, Chia-Ping H.; Band Horwitz, Susan.

In: International Journal of Molecular Sciences, Vol. 18, No. 8, 1733, 10.08.2017.

Research output: Contribution to journalReview article

@article{62df772250ee4e049ee777d7eb4e7926,
title = "Taxol{\circledR}: The first microtubule stabilizing agent",
abstract = "Taxol{\circledR}, an antitumor drug with significant activity, is the first microtubule stabilizing agent described in the literature. This short review of the mechanism of action of Taxol{\circledR} emphasizes the research done in the Horwitz’ laboratory. It discusses the contribution of photoaffinity labeled analogues of Taxol{\circledR} toward our understanding of the binding site of the drug on the microtubule. The importance of hydrogen/deuterium exchange experiments to further our insights into the stabilization of microtubules by Taxol{\circledR} is addressed. The development of drug resistance, a major problem that arises in the clinic, is discussed. Studies describing differential drug binding to distinct β-tubulin isotypes are presented. Looking forward, it is suggested that the β-tubulin isotype content of a tumor may influence its responses to Taxol{\circledR}.",
keywords = "Drug binding site, Drug resistance, Photoaffinity labeling, Taxol{\circledR}, Tubulin isotypes",
author = "Yang, {Chia-Ping H.} and {Band Horwitz}, Susan",
year = "2017",
month = "8",
day = "10",
doi = "10.3390/ijms18081733",
language = "English (US)",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Taxol®

T2 - The first microtubule stabilizing agent

AU - Yang, Chia-Ping H.

AU - Band Horwitz, Susan

PY - 2017/8/10

Y1 - 2017/8/10

N2 - Taxol®, an antitumor drug with significant activity, is the first microtubule stabilizing agent described in the literature. This short review of the mechanism of action of Taxol® emphasizes the research done in the Horwitz’ laboratory. It discusses the contribution of photoaffinity labeled analogues of Taxol® toward our understanding of the binding site of the drug on the microtubule. The importance of hydrogen/deuterium exchange experiments to further our insights into the stabilization of microtubules by Taxol® is addressed. The development of drug resistance, a major problem that arises in the clinic, is discussed. Studies describing differential drug binding to distinct β-tubulin isotypes are presented. Looking forward, it is suggested that the β-tubulin isotype content of a tumor may influence its responses to Taxol®.

AB - Taxol®, an antitumor drug with significant activity, is the first microtubule stabilizing agent described in the literature. This short review of the mechanism of action of Taxol® emphasizes the research done in the Horwitz’ laboratory. It discusses the contribution of photoaffinity labeled analogues of Taxol® toward our understanding of the binding site of the drug on the microtubule. The importance of hydrogen/deuterium exchange experiments to further our insights into the stabilization of microtubules by Taxol® is addressed. The development of drug resistance, a major problem that arises in the clinic, is discussed. Studies describing differential drug binding to distinct β-tubulin isotypes are presented. Looking forward, it is suggested that the β-tubulin isotype content of a tumor may influence its responses to Taxol®.

KW - Drug binding site

KW - Drug resistance

KW - Photoaffinity labeling

KW - Taxol®

KW - Tubulin isotypes

UR - http://www.scopus.com/inward/record.url?scp=85027102573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027102573&partnerID=8YFLogxK

U2 - 10.3390/ijms18081733

DO - 10.3390/ijms18081733

M3 - Review article

C2 - 28792473

AN - SCOPUS:85027102573

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 8

M1 - 1733

ER -